Y-mAbs Therapeutics Q2 2024 Earnings Report $7.81 -0.36 (-4.41%) As of 04:00 PM Eastern Earnings HistoryForecast Y-mAbs Therapeutics EPS ResultsActual EPS-$0.21Consensus EPS -$0.13Beat/MissMissed by -$0.08One Year Ago EPS-$0.14Y-mAbs Therapeutics Revenue ResultsActual Revenue$22.80 millionExpected Revenue$23.09 millionBeat/MissMissed by -$290.00 thousandYoY Revenue GrowthN/AY-mAbs Therapeutics Announcement DetailsQuarterQ2 2024Date8/12/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseYMAB Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Y-mAbs Therapeutics Earnings HeadlinesY-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | globenewswire.comWe're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash WiselyDecember 20, 2024 | finance.yahoo.comBorn out of bankruptcy, it’s produced 50% per year… There is a wealth phenomenon that has delivered 50% returns per year, on average… And now that Trump is back in office, will likely continue to outperform every other asset by a wide margin. January 6, 2025 | Porter & Company (Ad)Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdlesDecember 19, 2024 | uk.investing.comPositive Outlook and Investment Potential for Y-Mabs Therapeutics: Buy Rating with Promising Preclinical and Clinical DevelopmentsDecember 14, 2024 | markets.businessinsider.comPromising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs TherapeuticsDecember 13, 2024 | markets.businessinsider.comSee More Y-mAbs Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Y-mAbs Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Y-mAbs Therapeutics and other key companies, straight to your email. Email Address About Y-mAbs TherapeuticsY-mAbs Therapeutics (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.View Y-mAbs Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
